Meitheal Brings In Another Three US Biosimilars
Adds Filgrastim, Pegfilgrastim And Follitropin Alfa To Pipeline
Meitheal has announced a licensing agreement with parent company Hong Kong King-Friend to add another three biosimilars to its pipeline for the US market.
